Trials / NCT03561922
Impact on Daily Life of Patients Using the Subretinal Implant RETINA IMPLANT Alpha AMS
Terminated N/A Gene therapy, Retinal implant
Why it stopped: Manufacturer of the investigational device has ceased all business activities
- Sponsor
- Retina Implant AG
- Treatment
- RETINA IMPLANT Alpha AMS
- Gene
- Not stated
- Conditions
- Retinal Degeneration, Inherited Retinal Dystrophy Primarily Involving Sensory Retina
- Ages
- 18 Years to 78 Years
- Enrollment
- 2 participants
- Started
- 2018-09-04
- Main results expected
- 2019-04-05
- Results posted
- Not yet
- Record last updated
- 2019-04-19
What the study is testing
This study aims to assess the impact of the subretinal implant RETINA IMPLANT Alpha AMS on the patient's daily life, using validated activities of daily living and questionnaires.
Where it runs
France (2)
- Clinique Saint Jean, Montpellier, Hérault
- Centre Hospitalier Universitaire La Milétrie de Poitiers, Poitiers, Vienne